» Articles » PMID: 36407858

Low-cost Zeolitic Carriers for Delivery of Hydroxychloroquine Immunomodulatory Agent with Antiviral Activity

Overview
Publisher Elsevier
Date 2022 Nov 21
PMID 36407858
Authors
Affiliations
Soon will be listed here.
Abstract

The coronavirus pandemic prompted scientists to look for active pharmaceutical ingredients that could be effective in treating COVID-19. One of them was hydroxychloroquine, an antimalarial and immunomodulatory agent exhibiting antiviral activity. The anchoring of this drug on porous carriers enables control of its delivery to a specific place in the body, and thus increases bioavailability. In this work, we developed low-cost zeolitic platforms for hydroxychloroquine. The waste solution generated during zeolite production from fly ashes was used in the synthesis of Na-A and Na-X carriers at laboratory and technical scale. The materials were characterized by high purity and single mineral phase composition. The surface charge of zeolites varied from negative at pH 5.8, and 7.2, to positive at pH 1.2. All samples indicated good sorption ability towards hydroxychloroquine. The mechanism of drug adsorption was based on electrostatic interactions and followed the Freundlich model. Zeolitic carriers modified the hydroxychloroquine release profiles at conditions mimicking the pH of body fluids. The mode of drug liberation was affected by particle size distributions, morphological forms, and chemical compositions of zeolites. The most hydroxychloroquine controlled release at pH 5.8 for the Na-X material was noted, which indicates that it can enhance the drug therapeutic efficacy.

Citing Articles

Application of Ordered Porous Silica Materials in Drug Delivery: A Review.

Liu W, Wu J, Jiang Z, Zhang X, Wang Z, Meng F Molecules. 2024; 29(23).

PMID: 39683872 PMC: 11643771. DOI: 10.3390/molecules29235713.


Improving the Dispersibility of TiO in the Colloidal System Using Trifunctional Spherosilicates.

Sztorch B, Nowak K, Frydrych M, Lesniewska J, Krysiak K, Przekop R Materials (Basel). 2023; 16(4).

PMID: 36837072 PMC: 9963084. DOI: 10.3390/ma16041442.

References
1.
Saghir S, AlGabri N, Alagawany M, Attia Y, Alyileili S, Elnesr S . Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. Ther Clin Risk Manag. 2021; 17:371-387. PMC: 8092643. DOI: 10.2147/TCRM.S301817. View

2.
Self W, Semler M, Leither L, Casey J, Angus D, Brower R . Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(21):2165-2176. PMC: 7653542. DOI: 10.1001/jama.2020.22240. View

3.
Souza I, Borrego-Sanchez A, Sainz-Diaz C, Viseras C, Pergher S . Study of Faujasite zeolite as a modified delivery carrier for isoniazid. Mater Sci Eng C Mater Biol Appl. 2020; 118:111365. DOI: 10.1016/j.msec.2020.111365. View

4.
Panek R, Medykowska M, Szewczuk-Karpisz K, Wisniewska M . Comparison of Physicochemical Properties of Fly Ash Precursor, Na-P1(C) Zeolite-Carbon Composite and Na-P1 Zeolite-Adsorption Affinity to Divalent Pb and Zn Cations. Materials (Basel). 2021; 14(11). PMC: 8199610. DOI: 10.3390/ma14113018. View

5.
Martins-Filho P, Ferreira L, Heimfarth L, Araujo A, Quintans-Junior L . Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am. 2021; 2:100062. PMC: 8403035. DOI: 10.1016/j.lana.2021.100062. View